Tango Therapeutics
Tango Therapeutics leverages synthetic lethality and CRISPR-based target discovery to develop medicines for genetically defined subsets of cancers with limited treatment options. The company is conducting multiple Phase 1/2 clinical trials and has a strategic collaboration with Gilead Sciences.
Company Background
Founded in 2017, Tango Therapeutics is a precision medicine company aiming to address the broad unmet needs in cancer treatment. The company leverages the principle of synthetic lethality to develop oncology medicines targeting specific tumors. Their mission is to become a fully-integrated biotechnology company, bringing transformative medicines to people with cancer.
Technology and Pipeline
Tango Therapeutics uses a CRISPR-based target discovery engine to identify and validate novel targets. Their pipeline consists of programs for genetically defined subsets of cancers with limited treatment options. Key programs include TNG908, TNG462, TNG260, and TNG348, which are in various stages of Phase 1/2 clinical trials. These trials are exploring the safety, efficacy, and dosage of the drugs in specific tumor types.
Clinical Trials
Tango Therapeutics conducts several clinical trials to evaluate their novel therapies. TNG908 is in a Phase 1/2 first-in-human trial for MTAP-deleted tumors. TNG462 is enrolling patients in a Phase 1/2 trial for MTAP-deleted cancers. TNG260 is in the dose-escalation portion of a Phase 1/2 trial, being evaluated in combination with pembrolizumab for STK11-mutant cancers. TNG348 is being tested as a single agent and in combination with olaparib in a Phase 1/2 trial.
Strategic Collaborations
Tango Therapeutics has a global strategic collaboration with Gilead Sciences focused on the discovery, development, and commercialization of targeted immune evasion therapies. This collaboration aims to advance the development of novel therapies to treat various forms of cancer. Despite this partnership, Tango retains all rights to its three lead programs and targets identified outside of the immune evasion space.
Scientific Approach
Tango Therapeutics employs high-throughput CRISPR-based functional genomics screening to identify synthetic lethal vulnerabilities in cancer cells. Their approach focuses on diseases with high unmet needs where patients share a common genetic context. The company has built a state-of-the-art functional genomics target discovery platform and a powerful bio-analytic pipeline to support the development of their innovative cancer therapies.